Executive Officers

Ms. Cynthia L. Sullivan has been employed by Immunomedics since October 1985, and has served as our President and Chief Executive Officer since March 2001. She previously served as the Company’s President from December 2000 to March 2001 and as Executive Vice President and Chief Operating Officer from June 1999 to December 2000. Prior to joining Immunomedics, Ms. Sullivan was employed by Ortho Diagnostic Systems, Inc., a subsidiary of Johnson & Johnson. Ms. Sullivan’s educational background includes: a B.S. from Merrimack College, North Andover, Massachusetts, followed by a year of clinical internship with the school of Medical Technology at Muhlenberg Hospital, Plainfield, New Jersey, resulting in a M.T. (ASCP) certification in 1979. Ms. Sullivan completed a M.S. degree in 1986 from Fairleigh Dickinson University, where she also received her M.B.A. in December 1991. Ms. Sullivan also serves as President of our majority owned subsidiary, IBC Pharmaceuticals, Inc. From September 2002 to July 2007, Ms. Sullivan served as a member of the Board of Directors of Digene Corp., a company that develops, manufactures and markets proprietary DNA and RNA testing systems for the screening, monitoring and diagnosis of human diseases. Effective July 30, 2007 Digene Corp was merged with Qiagen N.V. In November, 2007, Ms. Sullivan was appointed to serve as a member of the Board of Directors of Urigen Pharmaceuticals, Inc., a specialty pharmaceutical company focused on the development and commercialization of treatments for urological disorders. As of May, 2009, Ms. Sullivan also serves as a member of Board of Trustees for the HealthCare Institute of New Jersey, a trade association for the research-based pharmaceutical and medical technology industry in New Jersey.

Dr. David M. Goldenberg founded Immunomedics in July 1982, and has served continuously since that time as the Chairman of our Board of Directors. He also currently serves as our Chief Scientific Officer and Chief Medical Officer, having been our Chief Strategic Officer from July 2003 to July 2007. Dr. Goldenberg previously served as our Chief Executive Officer from July 1982 through July 1992, from February 1994 through May 1998 and from July 1999 through March 2001. He also serves as Chairman of the Board of Directors of IBC Pharmaceuticals, Inc., a subsidiary of Immunomedics. Dr. Goldenberg is a graduate of the University of Chicago College and Division of Biological Sciences (B.S.), the University of Erlangen-Nuremberg (Germany) Faculty of Natural Sciences (Sc.D.), and the University of Heidelberg (Germany) School of Medicine (M.D.). He has written or co-authored approximately 1,700 journal articles, book chapters and abstracts on cancer research, detection and treatment, and has researched and written extensively in the area of radioimmunodetection and radioimmunotherapy using radiolabeled antibodies. In addition to his position with Immunomedics, Dr. Goldenberg is President and a Trustee of the Center for Molecular Medicine and Immunology (“CMMI”), an independent non-profit research center, and its clinical unit, the Garden State Cancer Center. In 1985 and again in 1992, Dr. Goldenberg received an “Outstanding Investigator Grant” award from the National Cancer Institute for his work in radioimmunodetection, and in 1986 he received the New Jersey Pride Award in Science and Technology. Dr. Goldenberg was honored as the ninth Herz Lecturer of the Tel Aviv University Faculty of Life Sciences. In addition, he received the 1991 Mayneord 3M Award and Lectureship of the British Institute of Radiology and in 2002, the Elis Bervin Lectureship and Medal from the Swedish Medical Society and the Swedish Oncology Society for his contributions to the development of radiolabeled monoclonal antibodies used in the imaging and treatment of cancer. The International Society for Oncodevelopmental Biology and Medicine named Dr. Goldenberg the co-recipient of the 1994 Abbott Award. In 2005, he received the Paul Aebersold Award from the Society of Nuclear Medicine and was named the Inventor of the Year by the Research and Development Council of New Jersey. Maryann Liebert Inc., publisher of Genetic Engineering News, nominated Dr. Goldenberg in 2006 for the Forbes Enterprise Award for outstanding achievements in the scientific community.

Gerard G. Gorman has served as our Senior Vice President, Finance and Business Development, and Chief Financial Officer since June 2006 and Vice President, Finance and Chief Financial Officer from September 2001 until June 2006. From 1996 to 2001, Mr. Gorman was employed by the Animal Health Division of Pfizer Inc., where he was Vice President, Finance and Information Technology and Chief Financial Officer. While at Pfizer, Mr. Gorman directed strategic and long-range financial planning as well as negotiations related to acquisitions, divestitures and outsourcing of support operations. Mr. Gorman previously held a variety of other senior positions at Pfizer, including: Senior Director, Corporate Treasury Operations; Director, Administration—International Pharmaceuticals Group; Director, Finance/Assistant Treasurer International; and Manager, Benefit Financing/Senior Financial Analyst. Mr. Gorman completed a B.A. in economics from Fairfield University and received his M.B.A. from Adelphi University. Mr. Gorman also serves as a member of the Board of Directors of the Northern Ireland Children’s Enterprise.

Board of Directors

Dr. Morton Coleman has been Clinical Professor of Medicine at the Weill Medical College of Cornell University since 1986 and the Director of the Center for Lymphoma and Myeloma in the Division of Hematology–Oncology since 1997, at New York Presbyterian Hospital–Cornell Medical Center.  Dr. Coleman is the Chairman of the Medical Advisory Board and serves on both the Executive Committee of the Board of Directors and the Scientific Advisory Board of the Lymphoma Research Foundation.  He also serves on the Scientific Review boards of the International Waldenstrom’s Macroglobulinemia Foundation and the Lymphoma Foundation.  He is chairman of the Fund for Blood and Cancer Research, has served on or chaired a number of committees or subcommittees of the American Society of Clinical Oncology, is an Associate Editor of the journals, Cancer Investigation and Acta Haematologica, is past President of the New York Cancer Society, and was Chairman of the Affiliated Physicians Network, Inc.  He chaired the New Agents Committee and currently is a member of the Lymphoma Core Committee of Cancer and Leukemia Group B.  He has served on a number of review committees of the National Cancer Institute among other distinguished appointments.

Brian A. Markison currently serves as President, Chief Executive Officer and Chairman of the Board of Directors of King Pharmaceuticals, Inc.  Prior to joining King Pharmaceuticals, Mr. Markison was the President of Oncology, Virology and Oncology Therapeutics Network Business at Bristol-Meyers Squibb.  During his 22-year career at Bristol-Meyers Squibb, he distinguished himself in the areas of sales, marketing, international and domestic general management positions.

Mary E. Paetzold is a retired Certified Public Accountant with over 35 years of experience with public and private companies. From 2008 to 2009, she was an Adjunct Professor at the Cameron School of Business, University of North Carolina – Wilmington.  From 1994 to 2000 she was Vice President, Chief Financial Officer, Secretary, Treasurer and a member of the Board of Directors of Ecogen, Inc.  Prior thereto, Ms. Paetzold was an audit partner and SEC reviewing partner for KPMG LLP, in Short Hills, New Jersey, where she worked for 21 years.  She also served as chairperson of the Advisory Council of the School of Business at Montclair State University, where she earned an undergraduate degree in mathematics. Ms. Paetzold serves as a Director of Orthovita, a leading orthobiologics and biosurgery company.

Don C. Stark is the Chief Executive Officer and President of Whistler Associates, Inc., a marketing and strategic planning consulting firm for companies focused on oncology.  Prior to founding Whistler Associates, Inc., in 1996, Mr. Stark held various market research, marketing and business development positions at Bristol-Myers Squibb Oncology Division, Immunex, and Repligen, all in the fields of oncology and immunology.  Mr. Stark has concurrently served as partner and member of the Board of Directors of Strategic Answers Inc., a forecasting and information service provider to the pharmaceutical industry. 

Dr. Edward T. Wolynic has been a Board member of venture capital-backed technology startups and consultant to corporations in the advanced materials, energy and chemicals sector since 2006.  From 2000 through 2006 he was Chief Technology Officer and Vice President and from 1995 to 2000 Executive Director of the Strategic Technologies Group at Engelhard Corporation, a leading surface and materials science company.  Prior to joining Engelhard, Dr. Wolynic held various positions with International Specialty Products, UOP, Union Carbide and Merck.  Dr. Wolynic holds a BS in Chemical Engineering from Polytechnic Institute of Brooklyn, a MS in Chemical Engineering and a PhD in Chemical Engineering from Princeton University.